Press Releases July 30, 2026 06:00 PM

Sanuwave Will Host a Conference Call on August 7, 2026 at 8:30 AM (ET) to Present Q2 2026 Financial Results

Sanuwave Health to Present Q2 2026 Financial Results in Upcoming Conference Call

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
SNWV

Sanuwave Health, Inc., a NASDAQ-listed company specializing in FDA-approved wound care and regenerative medicine products, announced it will host a conference call on August 7, 2026, to discuss its Q2 2026 financial results. The company focuses on developing non-invasive medical systems for tissue repair and regeneration across various medical fields.

Sanuwave Will Host a Conference Call on August 7, 2026 at 8:30 AM (ET) to Present Q2 2026 Financial Results
SNWV
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Sanuwave will present its financial performance for Q2 2026 during a scheduled conference call on August 7.
  • The company develops next-generation wound care and regenerative medicine products using patented energy transfer technologies.
  • Sanuwave's products target skin, musculoskeletal, vascular, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular applications.

EDEN PRAIRIE, Minn., July 30, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, August 7, 2026, at 8:30 AM (ET) to present its Q2 2026 financial results.

Telephone access to the call will be available by dialing the following numbers:

Participant Dial-in Information
Toll Free: 1-800-274-8461
Toll/International: 1-203-518-9814
Conference ID: SANUWAVE

OR click the link below to access the live webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1771327&tp_key=110b588de5
Materials for the conference call will be included on the Company’s website at
www.sanuwave.com/investors.

A replay will be made available through Friday, August 21, 2026:

Toll-Free: 1-844-512-2921
Toll/International: 1-412-317-6671
Replay Access ID: 11162356

About Sanuwave

Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

Contact:
[email protected]


Risks

  • Risks related to regulatory oversight impacting product approvals and commercialization.
  • Uncertainties in managing capital resources effectively to support ongoing research and development.
  • Competitive pressures in the medical device and regenerative medicine sectors may affect market position.

More from Press Releases

Telix H1 2026 Results: Investor Webcast Notification Jul 30, 2026 Inno Holdings Inc. Updates Trading Time for the Resumption of Trading on Nasdaq Jul 30, 2026 OceanFirst Financial Corp. Announces Second Quarter Financial Results Jul 30, 2026 Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma Jul 30, 2026 Shinhan Bank Selects StoneX Payments as Strategic Cross-Border Payments Partner Jul 30, 2026